New hope for rare liver infection: RBD1016 trial underway
Disease control
Ongoing
This study tests an experimental drug called RBD1016 in 14 adults with chronic hepatitis D, a serious liver infection. The main goal is to see if the drug can lower the amount of virus in the blood over 60 weeks. Participants receive either RBD1016 or a placebo and visit the clin…
Phase: PHASE2 • Sponsor: Ribocure Pharmaceuticals AB • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC